RT Journal Article
SR Electronic
T1 High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.16.20195446
DO 10.1101/2020.09.16.20195446
A1 Kainulainen, Markus H.
A1 Bergeron, Eric
A1 Chatterjee, Payel
A1 Chapman, Asheley P.
A1 Lee, Joo
A1 Chida, Asiya
A1 Tang, Xiaoling
A1 Wharton, Rebekah E.
A1 Mercer, Kristina B.
A1 Petway, Marla
A1 Jenks, Harley M.
A1 Flietstra, Timothy D.
A1 Schuh, Amy J.
A1 Satheshkumar, Panayampalli S.
A1 Chaitram, Jasmine M.
A1 Owen, S. Michele
A1 Finn, M. G.
A1 Goldstein, Jason M.
A1 Montgomery, Joel M.
A1 Spiropoulou, Christina F.
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.16.20195446.abstract
AB SARS-CoV-2 emerged in late 2019 and has since spread around the world, causing a pandemic of the respiratory disease COVID-19. Detecting antibodies against the virus is an essential tool for tracking infections and developing vaccines. Such tests, primarily utilizing the enzyme-linked immunosorbent assay (ELISA) principle, can be either qualitative (reporting positive/negative results) or quantitative (reporting a value representing the quantity of specific antibodies). Quantitation is vital for determining stability or decline of antibody titers in convalescence, efficacy of different vaccination regimens, and detection of asymptomatic infections. Quantitation typically requires two-step ELISA testing, in which samples are first screened in a qualitative assay and positive samples are subsequently analyzed as a dilution series. To overcome the throughput limitations of this approach, we developed a simpler and faster system that is highly automatable and achieves quantitation in a single-dilution screening format with sensitivity and specificity comparable to those of ELISA.One sentence summary Protein complementation enables mix-and-read SARS-CoV-2 serology that rivals sensitivity and specificity of ELISA but excels in throughput and quantitation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual specimen materials were used for diagnostics development under a protocol that was reviewed and approved by the CDC Institutional Review Board (See 45 C.F.R. part 46; 21 C.F.R. part 56)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external data links